U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07218432) titled 'A Study of the TheraBionic P1 Device in Breast Cancer' on Sept. 09.
Brief Summary: The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage IIIA
Hormone Receptor Positive Tumor
HER2-negative Breast Cancer
Intervention:
DEVICE: TheraBionic P1 Device
Amplitude-modulated electromagnetic fields will be sel...